Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …

Background The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation
(HSCT) recipients is almost uniformely considered poor. The aim of present study was to …

Background Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of
mortality and morbidity with coronavirus disease 2019 (COVID‐19) due to severe immune …

We read with great interest the paper by He et al.[1] on the outcome of COVID-19 infection in
hematological malignancy patients. This study was one of the first to report the outcome in …

This study reports on 382 COVID-19 patients having undergone allogeneic (n= 236) or
autologous (n= 146) hematopoietic cell transplantation (HCT) reported to the European …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), emerged in China in December 2019 and rapidly spread …

There are currently limited data on the epidemiology, clinical manifestations, and optimal
management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation …

Bartholomew's Hospital, 2Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary
University of London, 3Department of Haematology, Barts Health NHS Trust, Whipps Cross …

BACKGROUND Understanding outcomes and immunologic characteristics of cellular
therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus of
zoonotic origin that emerged in China at the end of 2019. The infection, named Coronavirus …